Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication regarding basis of allotment of Equity Shares under Rights Issue of the Company
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valiant Laboratories has completed its Rights Issue, allotting 1,08,62,500 fully paid-up equity shares at ₹75 per share (face value ₹10, premium ₹65), aggregating ₹81.47 crores in a 1-for-4 ratio. The issue was oversubscribed at 132.96%, with 3,143 valid applications received for 1,44,42,794 shares against the 1,08,62,500 shares on offer; 310 applications for 1,71,743 shares were rejected on technical grounds. The Rights Issue Committee approved the allotment on August 11, 2025, and shares have been credited to demat accounts, with trading expected to begin on BSE on or about August 13, 2025. Direct shareholders received 71.20% of the allotted shares, while non-renouncees got 25.63% and renouncees 3.17%.
The oversubscribed rights issue signals strong shareholder confidence, with the company successfully raising ₹81.47 crores. Existing shareholders should see the new shares credited to their demat accounts, and trading on BSE is set to begin around August 13, 2025, which may lead to short-term price adjustments as the new shares enter the market.